Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCPVax plus Nivolumab in advanced NSCLC
NCT04263051Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of UCPVax in non-small cell lung cancer (NSCLC), sponsored by CHU de Besançon. Started Sep 2020; status: completed.
02
Drugs
UCPVax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04263051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263051.